Ceftolozane/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections : current perspectives and place in therapy
Escolà-Vergé, Laura (Hospital Universitari Vall d'Hebron)
Pigrau, Carlos (Hospital Universitari Vall d'Hebron)
Almirante Gragera, Benito (Hospital Universitari Vall d'Hebron)
Universitat Autònoma de Barcelona

Fecha:	2019
Resumen:	The current prevalence of infections caused by multidrug-resistant (MDR) organisms is a global threat, and thus, the development of new antimicrobial agents with activity against these pathogens is a healthcare priority. Ceftolozane-tazobactam (C/T) is a new combination of a cephalosporin with a β-lactamase inhibitor that shows excellent in vitro activity against a broad spectrum of Enterobacteriaceae and Pseudomonas aeruginosa, including extended spectrum β-lactamase-producing (ESBL) strains and MDR or extensively drug-resistant (XDR) P. aeruginosa. In phase III randomized clinical trials, C/T demonstrated similar efficacy to meropenem for the treatment of complicated intra-abdominal infections (cIAIs) and superior efficacy to levofloxacin for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. The drug is generally safe and well tolerated and its PK/PD profile is very favorable. Observational studies with C/T have revealed good efficacy for the treatment of different types of infection caused by MDR or XDR P. aeruginosa, including some that originated from the digestive or urinary tracts. The place of C/T in therapy is not well defined, but its use could be recommended in a carbapenem-sparing approach for the treatment of infections caused by ESBL-producing strains or for the treatment of infections caused by P. aeruginosa if there are no other more favorable therapeutic options. Further clinical experience is needed to position this new antimicrobial drug for the empirical treatment of cIAIs or cUTIs.
Ayudas:	Instituto de Salud Carlos III REIPI RD16/0016/0003
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Publicado en:	Infection and drug resistance, Vol. 12 (2019) , p. 1853-1867, ISSN 1178-6973

DOI: 10.2147/IDR.S180905
PMID: 31308706

15 p, 369.4 KB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados